Loading
Latest filing published 01 Mar 2024 for Eagle Pharmaceuticals, INC., €12k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Scott Tarriff, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Eagle Pharmaceuticals, Inc. and Theriva Biologics, Inc. Over a trading history stretching from 4 January 2016 to 28 February 2024, the count stands at 51 filings.
Sales make up the whole of the open-market record (31 sales, €10.7M). Other entries cover 16 share grants and 3 option exercises.
The record was last updated on 1 March 2024 with a share grant (€12k) in Eagle Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
18 of 18 declarations